Reuters logo
10 months ago
BRIEF-Oncogenex says phase 3 ENSPIRIT trial of custirsen in non-small cell lung cancer did not meet primary endpoint
October 13, 2016 / 11:52 AM / 10 months ago

BRIEF-Oncogenex says phase 3 ENSPIRIT trial of custirsen in non-small cell lung cancer did not meet primary endpoint

Oct 13 (Reuters) - Oncogenex Pharmaceuticals Inc :

* Oncogenex announces results from the phase 3 ENSPIRIT trial of custirsen in non-small cell lung cancer

* Oncogenex Pharmaceuticals Inc - trial did not meet primary endpoint

* Oncogenex Pharmaceuticals -continuing to work with mts health partners who has been advising co in exploration of strategic alternatives since mid-August Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below